The invention relates to a blood-based tumor
mutation burden (bTMB) biomarker, and an measuring method and uses thereof. The bTMB biomarker is obtained from the following steps that
cell-
free DNA (cfDNA) is obtained from a blood sample of a subject, the number of somatic mutations on sequencing bases is measured, the number of somatic mutations of low
allele abundance is taken as the bTMB biomarker and expressed as LAF-bTMB, wherein the low
allele abundance means that the
allele frequency is less than, for example, 25%, 24%, 23%, 22%, 21%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%,9%, 8%, 7%, 6%, 5%, 4 %, 3%, 2%, 1%, for example, between 0.3% to 25%, preferably less than, for example, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, for example, between 0.5% to 13%, andparticularly preferably less than 6.5%, 6%, 5.5%, 5%, 4.5%, 4 %, 3.5%, 3%, 2.5%, and the LAF-bTMB is calculated according to the total number of mutations in a sample measuring area.